Swine Healthcare Market Size, Share & Trends Analysis Report By Product (Diagnostic Tests, Therapeutics), By Disease (Exudative Dermatitis (Greasy Pig Disease), Coccidiosis, Respiratory Diseases, Swine Dysentery, Porcine Parvovirus) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Overview

The global swine healthcare market size was valued at USD 2.77 billion in 2022. It is expected to reach USD 5.69 billion by 2031, growing at a CAGR of 8.3% during the forecast period (2023–2031).

Swine health refers to the illnesses brought on by pigs and the creation of treatments to stop the related ailment and disorders. Numerous illnesses, including congenital disabilities and reproductive disorders, can result from pig breeding. To protect and improve the health of swine, governmental organizations are launching programs that lessen the impact of swine diseases on humans. The global swine healthcare market is anticipated to be driven by rising investments in R&D activities for developing novel therapeutics, increasing government initiatives to prevent zoonotic diseases, and rising demand for livestock products.

Market Dynamics

Market drivers

Rising demand for livestock-related products

The demand for livestock products has increased globally due to rising consumer incomes and population growth, which is anticipated to propel market expansion. According to the Agricultural 2018-2027 report by the Food and Agriculture Organization (FAO) and the Organization for Economic Co-operation and Development (OECD), some of the significant contributors to global meat production include the United States, China, Argentina, India, Mexico, the Russian Federation, and Turkey. The largest meat producer in the world is the People's Republic of China. "Our World in Data 2019" statistics show that approximately 340 million tons of meat were produced worldwide in 2018. The market is also anticipated to benefit from the fact that pig meat is the most popular meat in the world. In addition, antibiotics have been used extensively in animal production around the world for several years to treat, prevent, and control disease outbreaks, as well as to speed up animal growth and boost productivity.

Rising investments in research and development to create novel pharmaceuticals

Researchers worldwide are concentrating on developing efficient new therapeutics to prevent and treat swine-related diseases. There is an increasing need for therapeutics, which is expected to drive market growth over the forecast period. The African swine fever (ASF) vaccine is being developed in China by the Harbin Veterinary Research Institute (HVRI), which is a part of the Chinese Academy of Agricultural Sciences (CAAS). According to China's Ministry of Agriculture and Rural Affairs (MARA), 10,000 pigs were introduced into the expanded clinical and production trial stage in August 2020. This is expected to positively impact the market as it may create a novel, effective vaccine for African swine fever (ASF) in China.

In addition, a contract to establish the Zoetis Incubator Research Lab and to launch a research collaboration on the livestock immune system was signed in July 2019 by Zoetis and Colorado State University. This agreement paves the way for new immunotherapies that could replace antibiotics in food-producing animals. Thus, it is anticipated that the market will grow over the forecast period due to rising research and development efforts in creating efficient novel therapeutics.

Market restraints

High costs related to pork health, particularly in developing countries

The most popular meat consumed worldwide is pork. However, managing swine-related diseases has resulted in rapidly rising treatment and diagnostic costs, which is expected to impede market expansion. One of the most severe infectious diseases of the gastrointestinal tract is swine dysentery, which affects pigs during the post-weaning and fattening phases. Swine dysentery is caused by the bacteria Brachyspira hyodysenteriae. For hog farmers worldwide, swine dysentery has resulted in sizable financial losses.

Additionally, it has an impact on a pig's capacity to consume food and put on weight, which could have an impact on feed efficiency. As a result, serological techniques like PCR or cell cultures are required for a differential diagnosis of the diseases. Still, their high cost in developing nations prevents the market from expanding. Thus, it is anticipated that the market's growth will be constrained over the forecast period.

Market opportunities

Development of new vaccines and diagnostic tests

Globally, rapid pig population losses and the sustainability of the world's food supply chain were caused by rapid outbreaks and the spread of African swine fever across China and other nations. Market players have a vast opportunity to manage swine-related diseases effectively by developing novel therapeutics to avoid such circumstances. Infectious diseases decrease farm animals' productivity, and the globalization of trade in animals and animal products increases the threat of disease incursion. The detection, control, and eradication of such diseases require accurate and quick diagnostic imaging techniques.

New imaging techniques may make it possible for veterinarians to use new tools to diagnose swine disease quickly and accurately, despite the widespread use of conventional diagnostic imaging. Diagnostic imaging biotechnologies are required methods that have recently been applied for the quick diagnosis and assessment of a wide variety of pathologies. These methods have largely replaced the traditional medical diagnostics used in veterinary medicine for decades.

Regional Analysis

The global swine healthcare market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.

North america dominates the global market

North America is the most significant shareholder in the global swine healthcare market and is expected to grow at a CAGR of 8.32% during the forecast period. Due to factors like rising pork consumption and rising per capita spending on animal healthcare, the United States is anticipated to maintain its sizeable market share. In addition, the prevalence of various animal diseases is rising, which has been identified as the primary driver of market expansion. According to a published article by Terri Queck-Matzie from 2019, the gross output of pork production in the United States was estimated to be USD 23.4 billion annually, with about 26% of the nearly 2.2 million metric tons of pork and pork products produced being exported. Additionally, due to the widespread distribution of feral pigs in the United States, the prevalence of classical swine fever (CSF) and swine influenza is rising.

Europe is expected to grow at a CAGR of 7.97% during the forecast period. The development of veterinary diagnostics and healthcare, as well as growing government initiatives, can be credited for expanding the German market. A research partnership between Boehringer Ingelheim and GNA Biosolutions was established in 2019 to develop a quick diagnostic test for African swine fever (ASF). Such partnerships between the nation's major players will accelerate regional market expansion. In addition, the German Cabinet recently approved new guidelines for using antibiotics in livestock as part of the DART 2020 German Antibiotic Resistances Strategy. These regulations impact the anti-infective sector of the nation.

In Asia-Pacific, the market for swine healthcare in China is expanding due to rising pork consumption and the threat of swine diseases. According to the Ministry of Agriculture and Rural Affairs, the first outbreak of African swine fever (ASF) was reported on August 3 in Liaoning Province, China. In recent years, China has seen increased public awareness of swine vaccinations and general health. Additionally, campaigns for animal rights and welfare have grown in China. To advance animal welfare in 2019, the World Small Animal Veterinary Association (WSAVA) partnered with ACT Asia, a nonprofit that offers veterinary education in China. The partnership supports the growth of the veterinary profession in China. Similarly, Zoetis enhanced animal vaccine research and development in China in 2018 to fight common diseases. The business anticipates that these vaccines will eventually play a significant role in this sector's use of health management tools. As a result, it is anticipated that the swine healthcare market in China will grow strongly during the anticipated period.

In the Middle East and Africa, the demand for livestock products has significantly increased in South Africa, and the prevalence of swine diseases is driving the regional market. Numerous international animal health firms with effective distribution networks throughout Africa, including IDEXX, Zoetis, Virbac, and others, are based in the nation. For instance, in March 2017, Cipla sold its animal health business in South Africa to Ascendis Health, a wholly-owned subsidiary that specializes in human, plant, and animal health.

The growth of the overall market has been facilitated by the rise in businesses making consistent efforts to improve animal healthcare. The nonprofit organization addressing ailments affecting farm animals and other animals is the South African Animal Health Association (SAAHA). The main factors propelling the swine healthcare market in the region over the forecast period are the rising government priorities toward more investment in animal healthcare, partnerships between players to better diagnose swine diseases, and the rising prevalence of diseases.

The prevalence and severity of the porcine respiratory disease complex (PRDC) in Brazil's swine herd were documented in a 2019 article published in the Porcine Health Management. Although the infection was widespread, good management techniques could stop the porcine respiratory disease complex (PRDC) from wreaking havoc on commercial pig herds, according to research on Brazil's outbreaks. In addition, the Brazilian Ministry of Agriculture also began a CSF eradication program in April 2019. Major Brazilian businesses also merge, acquire, and develop cutting-edge veterinary products to treat various animal diseases.

For instance, in April 2019, the Brazilian meat company JBS SA paid USD 59,643,000 to acquire the pork processor Adelle Indstria de Alimentos Ltd. through its subsidiary Seara Alimentos Ltda. The transaction must receive approval from the Brazilian Antitrust Authority and other customary conditions before it can be finished. Therefore, as a result of the factors above, it is anticipated that the Brazilian swine healthcare market will expand significantly over the forecast period.

Segmental Analysis

The global swine healthcare market is segmented by product and disease.

Based on the product, the global market is bifurcated into diagnostic tests and therapeutics.

The therapeutics segment is the highest contributor to the market and is expected to grow at a CAGR of 8.42% during the forecast period. The therapeutics segment is subdivided into vaccines, parasiticides, anti-infectives, and feed additives. Pigs are vaccinated, typically via parenteral administration, to elicit an immune response that may guard against later, unavoidable infection with the organism from which the vaccine was derived. According to data released by the National Pork Board in 2018, 40.1% of all meat consumed worldwide is consumed as pork per person, which suggests that effective vaccine treatments are required to maintain a healthy swine population.

Additionally, a huge demand for pork in developed nations and a sharp rise in government initiatives to promote animal husbandry fueling vaccine production. The market growth may be positively impacted by investments made by biotechnology companies in developing novel formulations with cutting-edge technologies to combat newly discovered viruses and newly approved drugs.

The diagnostic test is subdivided into Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Immuno Migration (RIM), Agar Gel Immunodiffusion (AGID), Polymerase Chain Reaction (PCR), and Diagnostic Imaging. A standard immunological assay for measuring antibodies, antigens, proteins, and glycoproteins in animal biological samples is the enzyme-linked immunosorbent assay (ELISA). Affected herds may benefit from screening using the ELISA test, which was effective at differentiating between infected and uninfected animals. Pigs with toxoplasma infection are frequently diagnosed using ELISA techniques. Additionally, they are used to identify positive farms for toxoplasmosis in pigs through slaughterhouse-based serological monitoring. The employed techniques vary in sensitivity and specificity and are non-standardized. The market is likely to grow due to increased attention being paid to research studies validating the effectiveness of ELISA tests in various rare and highly infectious diseases in pigs.

Based on disease, the global market is bifurcated into exudative dermatitis (greasy pig disease), coccidiosis, respiratory diseases, swine dysentery, and porcine parvovirus.

The respiratory diseases segment owns the highest contributor to the market and is expected to grow at a CAGR of 8.67% during the forecast period. Pleuropneumonia is a prevalent respiratory disease that negatively affects morbidity and mortality worldwide. These illnesses have the potential to harm infected animals and cost farmers money. In addition, early disease detection is necessary to lessen the burden of diseases and their adverse effects.

Computer vision technology can assist in the early detection of changes in swine physiology and the detection of Actinobacillus pleuropneumoniae infection in pigs by using RGB (red, green, and blue) and thermal infrared imagery. Additionally, a growing pig population globally indicates that pig production is becoming more popular and is a significant economic activity. As a result, the demand for diagnostics and therapeutics to treat respiratory diseases is rising, accelerating the market's expansion.

According to the MSD Veterinary Manual by Merck & Co. Inc., exudative epidermis, also known as greasy pig disease (GPD), is generalized dermatitis that affects 5- to 60-day-old pigs and is characterized by its sudden onset, with morbidity of 10-90% and mortality of 5-90%. The pig industry is financially burdened by the rising incidence of GPD, which increases the demand for cutting-edge treatments and diagnostics for disease management. According to data from the National Animal Disease Information Service, the disease can cost EUR 1000 plus treatment in sow breeder feeder farms with a 5% incidence over a year and can result in a loss of EUR 1200 in young pig mortality due to GPD. While the chronic form is more frequently observed in weaned pigs, the acute form typically affects suckling piglets. The primary clinical symptom is bacterially-induced dark patches of flaky, oily skin. Bacterial toxins can result in death.

Recent Developments

• January 2022- Tilmovet AC, the first generic tilmicosin phosphate aqueous concentrate for oral use in drinking water for swine, received approval from the Center for Veterinary Medicine of the United States Food and Drug Administration.
• November 2022- Royal DSM announced that FUMzyme, a fumonisin esterase, is commercially available for poultry and swine feed use in the United States. FUMzyme is the first pure enzyme licensed by the FDA for the selective and irreversible degradation of fumonisins into non-toxic metabolites.